Monograph Title Sort descending | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
ALLANTOIN | IDENTIFICATION | First Supplement to USP35–NF30 | 5429 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of B. Thin-Layer Chromatographic Identification Test <201>: Change The RF value of the principal spot from Sample solution A corresponds to that from Standard solution A, as described in the test for Organic Impurities. to: The… Read More |
ALLOPURINOL | USP Reference standards <11> | USP37–NF32 | 1649 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of USP Allopurinol Related Compound C RS: Change N-(4H-1,2,4-Triazol-4-yl)-1H-pyrazole-4-carboxamide. to: 5-(4H-1,2,4-Triazol-4-yl)-1H-pyrazole-4-carboxamide. |
ALLOPURINOL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP41–NF36 | 121 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 3 of USP Allopurinol Related Compound A RS: Change (C5H6N4O)2 · H2SO4 350.32 to: (C4H6N4O)2 · H2SO4 350.31 |
ALMOND OIL | SPECIFIC TESTS/Sterol Composition | USP36–NF31 | 1877 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Row 9 of Table 2: Change Δ7-Stigmastenol ≥3.0% to: Δ7-Stigmastenol ≤3.0% |
ALMOTRIPTAN MALATE | IMPURITIES/Limit of Almotriptan Related Compound D and Almotriptan N-Dimer | First Supplement to USP38–NF33 | 7325 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1of Internal standard solution: Change 4-hydroxy-phenylpiperidine to: 4-hydroxy-4-phenylpiperidine |
ALMOTRIPTAN MALATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Interim Revision Announcement (Official May 01, 2017) | Online | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine N-oxide. C17H25N3O3S 351.46 to: 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine N… Read More |
ALMOTRIPTAN TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP40–NF35 | 8708 | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 4 of USP Almotriptan Related Compound B RS: Change C15H22N3O2S to: C15H21N3O2S AND Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl… Read More |
ALMOTRIPTAN TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official February 01, 2017) | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 4 of USP Almotriptan Related Compound B RS: Change ½C4H4O to: ½C4H4O4 |
ALOSETRON HYDROCHLORIDE | IMPURITIES/Organic Impurities | USP43–NF38 | 141 | 24-Apr-2020 | 1-May-2020 | NA | NA | In System suitability/Suitability requirements/Resolution: Change NLT 7 to: NLT 3 |
ALPRAZOLAM EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP39–NF34 | 2389 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Variable definition list of second equation in Test 2/Analysis: Change VS = volume of the Sample solution withdrawn at each time point and replaced with Medium (mL) to: VS = volume of the Sample solution withdrawn at… Read More |
ALPRAZOLAM ORALLY-DISINTEGRATING TABLETS | IMPURITIES/Procedure | USP35–NF30 | 2106 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Change the subsection
Buffer and Diluent: Prepare as directed in the Assay. to: Diluent: Prepare as directed in the Assay. Buffer: 6.8 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 3.0. |
ALPROSTADIL | ASSAY/Procedure | USP42–NF37 | 151 | 26-Jul-2019 | 1-Aug-2019 | NA | NA | In System suitability stock solution: Change Standard solution to: Standard stock solution |
ALTEPLASE | ASSAY/Biological Potency | USP39–NF34 | 2398 | 29-Jan-2016 | 1-Feb-2016 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 1 of Human thrombin solution: Change 33 Units in terms of the U.S. Standard Thrombin/mL in Buffer to: 33 U.S. Units in terms of the U.S. Standard Thrombin/mL in Buffer AND Line 5 of Analysis: Change Standard solution and Sample solution… Read More |
ALTEPLASE FOR INJECTION | ASSAY/Biological Potency | USP39–NF34 | 2401 | 29-Jan-2016 | 1-Feb-2016 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 1 of Human thrombin solution: Change 33 Units in terms of the U.S. Standard Thrombin/mL in Buffer to: 33 U.S. Units in terms of the U.S. Standard Thrombin/mL in Buffer AND Line 5 of Analysis: Change Standard solution and Sample solution… Read More |
ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION | SPECIFIC TESTS/Microbial Enumeration Tests <61> and Tests for Specified Microorganisms <62> | USP42–NF37 | 170 | 26-Jul-2019 | 1-Aug-2019 | NA | NA | Change cfu/g to: cfu/mL |
ALUMINA, MAGNESIA, CALCIUM CARBONATE, AND SIMETHICONE CHEWABLE TABLETS | ASSAY/Magnesium Hydroxide | USP37–NF32 | 1674 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5 of Magnesium stock solution: Change Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg) to: Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of… Read More |
ALUMINUM CHLOROHYDRATE | CHEMICAL INFORMATION | USP38–NF33 | 2130 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 8: Change Dihydrate [12042-91-0].Anhydrous [1327-41-9]. to: Dihydrate [12359-72-7].Anhydrous [12042-91-0]. |
ALUMINUM CHLOROHYDRATE SOLUTION | ASSAY/Procedure 4 | USP37–NF32 | 1686 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Analysis: Change anhydrous aluminum dichlorohydrate to: anhydrous aluminum chlorohydrate |
AMANTADINE HYDROCHLORIDE | IDENTIFICATION | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In A.: Change Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197A, 197K, and 197S to: Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197A, 197K, or 197S Procedure for… Read More |
AMANTADINE HYDROCHLORIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP35–NF30 | 2153 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Chromatographic system: Change Column: 0.32-mm × 30-cm, 0.25-μm film, phase G1 to: Column: 0.32-mm × 30-m, 0.25-μm film, phase G1 |
AMIFOSTINE | ASSAY/Procedure/System suitability/Suitability requirements | USP37–NF32 | 1717 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Column efficiency: Change NLT 100 to: NLT 1000 |
AMIKACIN SULFATE | ASSAY | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Procedure/Analysis: Change CU = concentration of amikacin in the Sample solution (mg/mL) to: CU = concentration of Amikacin Sulfate in the Sample solution (mg/mL) |
AMIKACIN SULFATE INJECTION | ASSAY/Procedure | USP41–NF36 | 203 | 31-Aug-2018 | 1-Sep-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Variable definition list in Analysis: Change CU = nominal concentration of amikacin in the Sample solution to: CU = nominal concentration of amikacin in the Sample solution (mg/mL) |
AMINOBENZOATE POTASSIUM | IMPURITIES/Limit of Aniline and p-Toluidine | USP41–NF36 | 209 | 31-Aug-2018 | 1-Sep-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Line 3 of System suitability: Change [Note—The relative retention times of aniline and p-toluidine are about 4.1 and 5.1 min, respectively.] to: [Note—The relative retention times of aniline and p-toluidine are 0.8 and 1.0, respectively… Read More |
AMINOBENZOIC ACID | IMPURITIES/Organic Impurities | USP37–NF32 | 1730 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Add the subsection: Standard stock solution: 0.25 mg/mL each of USP Benzocaine RS and 4-nitrobenzoic acid in methanol AND Line 2 of Standard solution: Change in Mobile phase to: in Mobile phase, from the Standard stock solution |
AMINOPHYLLINE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 2735 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: Theophyllidine; N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride… Read More |
AMINOPHYLLINE INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 2737 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: Theophyllidine; N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride… Read More |
AMINOPHYLLINE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 2739 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: Theophyllidine; N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride… Read More |
AMINOPHYLLINE TABLETS | PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity | USP39–NF34 | 2483 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Variable definition for CU in Analysis: Change (mg/mL) to: to:(µg/mL) |
AMINOPHYLLINE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 2742 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: Theophyllidine; N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride… Read More |
AMINOSALICYLATE SODIUM | ASSAY/Procedure | USP37–NF32 | 1745 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 15 of Analysis: Change CU = concentration of aminosalicylate in the Sample solution (mg/mL) to: CU = concentration of Aminosalicylate Sodium in the Sample solution (mg/mL) |
Aminosalicylate Sodium | Limit of m-aminophenol | USP35–NF30 | 2177 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Test preparation: Change Use the Assay preparation, prepared as directed in the Assay. to: Transfer about 69 mg of Aminosalicylate Sodium, accurately weighed, to a 100-mL low-actinic volumetric flask, add 50 mL of Mobile phase, and swirl to dissolve.… Read More |
Aminosalicylate Sodium Tablets | Limit of m-aminophenol | USP35–NF30 | 2178 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Test solution: Change Use the Assay preparation, prepared as directed in the Assay. to: Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 690 mg of aminosalicylate sodium, to a 100-mL… Read More |
Aminosalicylic Acid Tablets | Limit of m-aminophenol | USP35–NF30 | 2179 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Change the subsection: Mobile phase and Internal standard solution—Prepare as directed in the Assay under Aminosalicylic Acid. to: Mobile phase—Prepare as directed in the Assay under Aminosalicylic Acid. Internal standard solution… Read More |
AMIODARONE HYDROCHLORIDE | ORGANIC IMPURITIES/Procedure 1/Chromatographic system | USP38–NF33 | 2198 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Adsorbent: Change 0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm to: Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm |
AMIODARONE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | Online | 20-Nov-2020 | 1-Dec-2020 | NA | NA | In USP Amiodarone Related Compound H RS: Change 2-Chloro-N,N-diethylethanamine. C6H14ClN 135.64 to: 2-Chloro-N,N-diethylethanamine hydrochloride. C6H14ClN · HCl 172.09 |
AMIODARONE HYDROCHLORIDE | IMPURITIES/Organic Impurities/Procedure 1 | USP37–NF32 | 1750 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Acceptance criteria: Change Standard solution B is not more intense to: the Sample solution is not more intense |
AMIODARONE HYDROCHLORIDE | IDENTIFICATION/A. | USP43–NF38 | Online | 25-Sep-2020 | 1-Oct-2020 | NA | NA | This erratum applies to the USP-NF online platform only. Change Infrared Absorption 〈197K〉 to: Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197K |
AMIODARONE HYDROCHLORIDE | CHEMICAL INFORMATION | USP42–NF37 | 253 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/september-2019-errata-with-image.pdf for correction. |
AMIODARONE HYDROCHLORIDE INJECTION | IMPURITIES/Limit of Iodide | USP43–NF38 | 254 | 25-Jun-2021 | 1-Jul-2021 | NA | NA | In Potassium iodate solution: Change 10.7 g/L of potassium iodide in water to: 10.7 g/L of potassium iodate in water |
AMITRIPTYLINE HYDROCHLORIDE | CHEMICAL INFORMATION | USP43–NF38 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | Change 313.86 to: 313.87 |
AMITRIPTYLINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43 |
AMITRIPTYLINE HYDROCHLORIDE | ASSAY/Procedure | USP43–NF38 | 261 | 26-Feb-2021 | 1-Mar-2021 | NA | NA | In System suitability solution: Change 0.5 µg/mL of USP Amitriptyline Related Compound A RS, 1 µg/mL of USP Amitriptyline Hydrochloride RS, and 1.5 µg/mL each of USP Amitriptyline Related Compound B RS, USP Cyclobenzaprine Hydrochloride RS, and USP… Read More |
AMITRIPTYLINE HYDROCHLORIDE TABLETS | IDENTIFICATION/A. | USP36–NF31 | 2464 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to: Sample stock solution: Nominally 0.1 mg/mL of… Read More |
AMITRIPTYLINE HYDROCHLORIDE TABLETS | IMPURITIES/Organic Impurities | Second Supplement to USP41–NF36 | 8759 | 22-Feb-2019 | 1-Mar-2019 | NA | NA | In Analysis: Change rU = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline hydrochloride from the Sample solution rS = peak response of amitriptyline related… Read More |
AMITRIPTYLINE HYDROCHLORIDE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 263 | 25-Jun-2021 | 1-Jul-2021 | NA | NA | In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43 |
AMLODIPINE AND ATORVASTATIN TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 265 | 20-Nov-2020 | 1-Dec-2020 | NA | NA | In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64 |
AMLODIPINE AND ATORVASTATIN TABLETS | ASSAY/Procedure | First Supplement to USP41–NF36 | 8270 | 23-Feb-2018 | 1-Mar-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | In the variable definition list of the second equation in Analysis: Change Mr2 = molecular weight of atorvastatin calcium, 1209.39 to: Mr2 = molecular weight of atorvastatin calcium, 1155.34 |
AMLODIPINE AND ATORVASTATIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP41–NF36 | 8270 | 23-Feb-2018 | 1-Mar-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | In the variable definition list of the second equation in Analysis: Change Mr2 = molecular weight of atorvastatin calcium, 1209.39 to: Mr2 = molecular weight of atorvastatin calcium, 1155.34 |
AMLODIPINE AND ATORVASTATIN TABLETS | IMPURITIES/Organic Impurities Related to Atorvastatin | First Supplement to USP41–NF36 | 8270 | 23-Feb-2018 | 1-Mar-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | In the variable definition list in Analysis: Change Mr2 = molecular weight of atorvastatin calcium, 1209.39 to: Mr2 = molecular weight of atorvastatin calcium, 1155.34 |